A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact

This publication has 22 references indexed in Scilit:

• Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement
  Pancreas, 2016
• Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer
  JAMA Surgery, 2016
• Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment
  Medicine, 2015
• National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival
  World Journal of Surgery, 2015
• Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
  New England Journal of Medicine, 2013
• Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi‐institutional survey by the Japanese Society of Pancreatic Surgery
  Journal of Hepato-Biliary-Pancreatic Sciences, 2013
• Classification of Surgical Complications
  Annals of Surgery, 2004
• The RECIST criteria: implications for diagnostic radiologists
  British Journal of Radiology, 2001
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI: Journal of the National Cancer Institute, 2000
• Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the Pancreas
  Archives of Surgery, 1992